Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2022-10-30 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于召开2022年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2022 second extraordinary general meeting of shareholders for 瑞康医药集团股份有限公司. It details the meeting time, location, voting procedures, agenda items, and proxy authorization. It does not contain financial statements or results but is an announcement related to a shareholders meeting. The document length is 4111 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2022-10-30 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the 21st meeting of the 4th Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It includes approval of the company's 2022 third quarter report and a change of company address along with amendments to the Articles of Association. The document is short (807 characters) and primarily reports on meeting resolutions and approvals rather than containing the full third quarter report itself. It does not contain detailed financial statements or substantive financial data, so it is not an Interim/Quarterly Report (IR). Instead, it is a regulatory announcement about the meeting decisions and approvals, fitting best under Regulatory Filings (RNS).
2022-10-30 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the 23rd meeting of the 4th Board of Directors of Ruikang Pharmaceutical Group Co., Ltd. It includes approval of the company's 2022 third quarter report, changes to the company registration address and articles of association, adjustments to credit limits, and the proposal to convene an extraordinary shareholders meeting. The document is a formal announcement of board meeting decisions rather than the full third quarter report itself. The length is short (1566 characters) and it does not contain detailed financial statements or substantive financial data, only a summary of resolutions. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) announcing board decisions and approvals related to financial and corporate matters.
2022-10-30 Chinese
关于公司提供担保进展情况的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 瑞康医药集团股份有限公司 regarding the progress of the company's provision of guarantees. It details the scope, amounts, and types of guarantees provided by the company and its subsidiaries, including financial data about the guaranteed entities and cumulative guarantee amounts. The document is structured as a formal announcement with tables and specific financial figures related to guarantees, but it does not contain comprehensive financial statements or full financial performance reports. It is not an annual or interim report, nor is it a call transcript or management report. The content fits the category of a regulatory announcement about financing activities, specifically about guarantees provided by the company, which aligns with a Capital/Financing Update (CAP). The document length is 3046 characters, which is relatively short but contains substantive financial data about guarantees, not just a brief notice or a certification. Therefore, the best classification is Capital/Financing Update (CAP).
2022-09-27 Chinese
半年报监事会决议公告
Report Publication Announcement Classification · 95% confidence The document is an announcement of the resolution passed by the Supervisory Board regarding the company's 2022 semi-annual report and its summary. It states that the Supervisory Board has reviewed and approved the 2022 semi-annual report, confirming its compliance with laws and accuracy. The document does not contain the actual financial statements or substantive financial data but rather announces the approval and directs readers to the full report on an external website. The document length is short (744 characters), and it serves as a formal announcement of the report's approval rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2022-08-29 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 年半年度报告摘要' which translates to '2022 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full semi-annual report for comprehensive details. The presence of substantive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is 2522 characters, which is sufficient for a summary but still contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2022
2022-08-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.